Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial

Background: We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged ≥18 years. Methods: This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healthy adults aged ≥18 years in Henan Province, China. P...

Full description

Bibliographic Details
Main Authors: Wanshen Guo, Kai Duan, Yuntao Zhang, Zhiming Yuan, Yan-Bo Zhang, Zejun Wang, Dongyang Zhao, Huajun Zhang, Zhiqiang Xie, Xinguo Li, Cheng Peng, Wei Zhang, Yunkai Yang, Wei Chen, Xiaoxiao Gao, Wangyang You, Xue-Wei Wang, Zhengli Shi, Yanxia Wang, Xu-Qin Yang, Lianghao Zhang, Lili Huang, Qian Wang, Jia Lu, Yong-Li Yang, Jing Guo, Wei Zhou, Xin Wan, Cong Wu, Wenhui Wang, Jianhui Du, Xuanxuan Nian, Xing-Hang Li, Shihe Huang, Shuo Shen, Shengli Xia, An Pan, Xiaoming Yang
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:EClinicalMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S258953702100290X

Internet

http://www.sciencedirect.com/science/article/pii/S258953702100290X

Similar Items